Relationship between chronic diseases and benign prostatic hyperplasia in middle-aged and older Chinese adults: A cross-sectional study based on CHARLS database

doi:10.3969/j.issn.1006-7795.2025.02.011

Abstract

Abstract: Objective To explore the correlation between chronic diseases and the risk of benign prostatic hyperplasia (BPH) in middle-aged and older Chinese man.Methods Data from the 2013 China Health and Retirement Longitudinal Study (CHARLS) were used, including 4 509 male participants aged 45 years and older. Chronic diseases and BPH diagnoses were obtained through a questionnaire survey. Logistic regression analysis was performed to identify independent risk factors for BPH. Restricted cubic splines (RCS) were used to explore the nonlinear relationship between variables and BPH prevalence, while stratified analyses were conducted to assess the differential impact of chronic diseases on BPH prevalence in different subgroups.Results Compared to patients without BPH, those with BPH had a significantly higher prevalence of comorbid chronic diseases, including hypertension, diabetes, chronic respiratory diseases, chronic heart disease, stroke, chronic kidney disease, chronic digestive diseases, arthritis or rheumatism, depression, and memory-related disorders. Multivariable Logistic regression analysis indicated that factors such as the 10-item Center for Epidemiological Studies Depression Scale (CESD-10) scores (OR = 1.043, 95% CI: 1.022－1.063, P < 0.001), chronic respiratory disease (OR = 1.518, 95% CI: 1.143－1.998, P = 0.003), chronic heart disease (OR = 1.515, 95% CI: 1.143－1.998, P = 0.003), chronic kidney disease (OR = 2.384, 95% CI: 1.799－3.137, P < 0.001), and chronic digestive disease (OR=1.427， 95%CI：1.129-1.796,P=0.003) were independently associated with the occurrence of BPH. RCS analysis demonstrated no non-linear association between age, BMI, and CESD-10 scores and BPH. Stratified analysis revealed that the influence of these chronic conditions on BPH remained constantly stable across different subgroups.Conclusion BPH is commonly comorbid with various chronic diseases. Future treatment strategies for BPH should consider the shared pathological mechanisms between BPH and these chronic conditions, with a focus on integrated interventions targeting common pathways.

Key words: CHARLS, Database, benign prostatic hyperplasia, chronic disease, correlation

CLC Number:

R697+.3

Ming Jie, Jin Song, Liu Zhanliang, Wang Zongwei, Niu Yinong. Relationship between chronic diseases and benign prostatic hyperplasia in middle-aged and older Chinese adults: A cross-sectional study based on CHARLS database[J]. Journal of Capital Medical University, 2025, 46(2): 252-262.

References

［1］Wang W Y, Guo Y W, Zhang D X, et al. The prevalence of benign prostatic hyperplasia in mainland China: evidence from epidemiological surveys［J］. Sci Rep, 2015, 5: 13546.
［2］Liu D W, Li C, Li Y Y, et al. Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019［J］. World J Urol, 2023, 41(12): 3629－3634.
［3］Djavan B, Margreiter M, Dianat S S. An algorithm for medical management in male lower urinary tract symptoms［J］. Curr Opin Urol, 2011, 21(1): 5－12.
［4］Zi H, Liu M Y, Luo L S, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021［J］. Mil Med Res, 2024, 11(1): 64.
［5］Park S, Ryu J M, Lee M. Quality of life in older adults with benign prostatic hyperplasia［J］. Healthcare (Basel), 2020, 8(2): 158.
［6］Hacker K. The burden of chronic disease［J］. Mayo Clin Proc Innov Qual Outcomes, 2024, 8(1): 112－119.
［7］Suarez Arbelaez M C, Nackeeran S, Shah K, et al. Association between body mass index, metabolic syndrome and common urologic conditions: a cross-sectional study using a large multi-institutional database from the United States［J］. Ann Med, 2023, 55(1): 2197293.
［8］Suzuki Y, Kaneko H, Okada A, et al. Benign prostatic hyperplasia and incident cardiovascular disease［J］. Circ J, 2024, 88(3): 408－416.
［9］Sarma A V, Kellogg Parsons J. Diabetes and benign prostatic hyperplasia: emerging clinical connections［J］. Curr Urol Rep, 2009, 10(4): 267－275.
［10］Zhao Y H, Hu Y S, Smith J P, et al. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS)［J］. Int J Epidemiol, 2014, 43(1): 61－68.
［11］Zhang W, Cao G, Sun Y, et al. Depressive symptoms in individuals diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia(LUTS/BPH)in middle-aged and older Chinese individuals: results from the China Health and Retirement Longitudinal Study［J］. J Affect Disord, 2022, 296: 660－666.
［12］Hsieh F Y, Bloch D A, Larsen M D. A simple method of sample size calculation for linear and logistic regression［J］. Stat Med, 1998, 17(14): 1623－1634.
［13］Lambert P C, Abrams K R, Jones D R, et al. Analysis of ambulatory blood pressure monitor data using a hierarchical model incorporating restricted cubic splines and heterogeneous within-subject variances［J］. Stat Med, 2001, 20(24): 3789－3805.
［14］Schauer I G, Rowley D R. The functional role of reactive stroma in benign prostatic hyperplasia［J］. Differentiation, 2011, 82(4/5): 200－210.
［15］Wu F C W, Tajar A, Pye S R, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study［J］. J Clin Endocrinol Metab, 2008, 93(7): 2737－2745.
［16］Rastrelli G, Vignozzi L, Corona G, et al. Testosterone and benign prostatic hyperplasia［J］. Sex Med Rev, 2019, 7(2): 259－271.
［17］Hata J, Harigane Y, Matsuoka K, et al. Mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia［J］. Int J Mol Sci, 2023, 24(14): 37511400.
［18］Cunha G R. Epithelio-mesenchymal interactions in primordial gland structures which become responsive to androgenic stimulation［J］. Anat Rec, 1972, 172(2): 179－195.
［19］Gacci M, Corona G, Sebastianelli A, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis［J］. Eur Urol, 2016, 70(5): 788－796.
［20］Peng Y H, Huang C W, Liao W C, et al. Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study［J］. BMJ Open, 2017, 7(6): 28645971.
［21］Kim H J, Park J W, Cho Y S, et al. Pathogenic role of HIF-1α in prostate hyperplasia in the presence of chronic inflammation［J］. Biochim Biophys Acta Mol Basis Dis, 2013, 1832(1): 183－194.
［22］Henein M Y, Vancheri S, Longo G, et al. The role of inflammation in cardiovascular disease［J］. Int J Mol Sci, 2022, 23(21): 12906.
［23］Zitzmann M. Testosterone deficiency and chronic kidney disease［J］. J Clin Transl Endocrinol, 2024, 37: 100365.
［24］Wang Q, Zhang B, Li B, et al. Correlation between benign prostatic hyperplasia/lower urinary tract symptoms and renal function in elderly men aged 80 years and older［J］. Clin Interv Aging, 2023, 18: 61－69.
［25］Black M, Slade A, Caras R J, et al. Evaluation of renal function recovery after Holmium laser enucleation of the prostate in patients with chronic kidney disease［J］. J Endourol, 2023, 37(7): 817－822.
［26］Rule A D, Lieber M M, Jacobsen S J.Is benign prostatic hyperplasia a risk factor for chronic renal failure?［J］.J Urol, 2005,173(3):691－696.
［27］Chen J, Chen B, Lin B, et al. The role of gut microbiota in prostate inflammation and benign prostatic hyperplasia and its therapeutic implications［J］. Heliyon, 2024, 10(19): e38302.
［28］Asare G A, Sule D S, Oblitey J N, et al. High degree of prostate related LUTS in a prospective cross-sectional community study in Ghana (Mamprobi)［J］. Heliyon, 2021, 7(11): e08391.
［29］Wang Y B, Yang L, Deng Y Q, et al. Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study［J］. J Transl Med, 2022, 20(1): 495.
［30］Xu X L, Sun M Q, Ye J F, et al. The effect of aromatase on the reproductive function of obese males［J］. Horm Metab Res, 2017, 49(8): 572－579.
［31］Xiong Y, Zhang Y C, Jin T, et al. Depressive males have higher odds of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a retrospective cohort study based on propensity score matching［J］. Asian J Androl, 2021, 23(6): 633－639.
［32］Yang L, Chen X, Liu Z, et al. The impact of illness perceptions on depressive symptoms among benign prostatic hyperplasia patients with lower urinary tract symptom［J］. Int J Gen Med, 2021, 14: 9297－9306.
［33］Xie Z L, Liu X B, Hu Z G, et al. Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)［J］. BMC Public Health, 2024, 24(1): 1121.
［34］Ohira T. Lower urinary tract symptoms secondary to benign prostatic hyperplasia and cardiovascular diseases in Japan-what is the next step?［J］. Circ J, 2021, 85(11): 2100－2101.
［35］Butt A K, Patel J, Shirwany H, et al. Beneficial extracardiac effects of cardiovascular medications［J］. Curr Cardiol Rev, 2022, 18(2): e151021197270.
［36］Pushpakom S, Iorio F, Eyers P A, et al. Drug repurposing: progress, challenges and recommendations［J］. Nat Rev Drug Discov, 2019, 18(1): 41－58.

[1]	Tian Xuanxuan, Ruan Xiangyan, Jin Jing, Ju Rui, Du Juan, Cheng Jiaojiao, Yang Yu. Analysis of sexual function of patients with polycystic ovary syndrome with different clinical phenotypes [J]. Journal of Capital Medical University, 2024, 45(4): 616-622.
[2]	Miao Mingyue, Su Rui, Zhou Yimin, Tian Ye, Yang Yanlin, Zhang Linlin, Zhou Jianxin. Correlation between pressure muscle index and inspiratory effort levels during pressure support ventilation: based on ASL5000 [J]. Journal of Capital Medical University, 2024, 45(2): 213-219.